AstraZeneca PLC

NASDAQ:AZNUnited States

Today

Show headlines and story abstract

• DJ AstraZeneca PLC Stock Falls Monday, Underperforms Market, from 11 hours ago by Dow Jones

  11 hours ago by Dow Jones
  Companies Mentioned: AZN
  
  This article was automatically generated using Dow Jones technology.
  
  Shares of AstraZeneca PLC dropped 0.1% to SEK1,689.50 Monday on what proved to be an overall mediocre trading session for the stock market, with the OMX Nordic 40 Index holding steady at 2,930.08.
  

• AstraZeneca's Tagrisso Secures Priority Review in the US, from 16 hours ago by MT Newswires

  16 hours ago by MT Newswires
  Companies Mentioned: AZN
  07:09 AM EDT, 06/10/2024 (MT Newswires) -- AstraZeneca (AZN) said Monday that its supplemental new drug application for Tagrisso has been accepted and granted priority review in the US for the treatment of adult patients with unresectable, stage III...

• TAGRISSO(R) (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer, from 16 hours ago by Dow Jones

  16 hours ago by Dow Jones
  Companies Mentioned: AZN
  lymphopenia, rash, diarrhea, stomatitis, nail toxicity, dry skin, and increased blood creatinine
  INDICATIONS
  -- TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test -- TAGRISSO is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test -- TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test -- TAGRISSO is indicated for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy
  

• --Berenberg Raises Price Target on AstraZeneca to GBP150 From GBP130, Cites More Confidence in Longer-Term Outlook, Keeps Buy Rating, from 16 hours ago by MT Newswires

  16 hours ago by MT Newswires
  Companies Mentioned: AZN
  06:39 AM EDT, 06/10/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contac...

• DJ AstraZeneca Looks Well on Track to Reach 2030 Revenue Target -- Market Talk, from 20 hours ago by Dow Jones

  20 hours ago by Dow Jones
  Companies Mentioned: AZN
  
  0614 GMT - AstraZeneca's oncology and biopharma upgrades move the Anglo-Swedish pharma giant closer to reaching its 2030 revenue goal, Berenberg analysts say in a note. Berenberg raised its 2030 revenue forecast for AstraZeneca to $74 billion, which narrows the gap on management's targeted revenue of $80 billion. More clarity on phase 3 trials and potential approval of its lung cancer drugs Tagrisso Laura, Imfinzi Adriatic and breast cancer drug Enhertu DB-06 by the year end could be further catalysts to help close the gap further, they say. Berenberg raised its sales forecasts across AstraZeneca's multiple marketed and pipeline drugs by $6 billion for 2030. (helena.smolak@wsj.com)